Metabolic disease definition

Metabolic disease means diabetes or metabolic syndrome.
Metabolic disease means diseases of metabolism, including, but not limited to, diabetes, obesity and Syndrome X, and excluding metabolic diseases of infectious pathogen origin or hosted by pathogen infection.

Examples of Metabolic disease in a sentence

  • Metabolic disease and cardiovascular risk in people treated with antipsychotics in the community.

  • This is why the areas where the infection is endemic, such as Asia, are the most affected by HCC;- Consumption of large amounts of alcohol, because of its implication in cirrhosis, is also an HCC risk factor which contributes more extensively in Western than in Asian countries;- Metabolic disease, and in particular obesity, are a growing cause of cirrhosis and HCC.Most HCCs are diagnosed at an advanced stage because the tumor progresses without any visible clinical manifestations in the early stages.

  • Jodi Flaws University of Illinois at Urbana-Champaign Metabolism and heart disease Metabolic disease and diabetes Assessing the effects of BPA exposure on development of metabolic syndrome by examining: gene expression; secretion of adipokines and cytokines; and adipose tissue cellularity.

  • Metabolic disease such as atherosclerosis and impaired glucose metabolism have been identified as contributing factors in tendinopathy.

  • These codes were grouped by a medical expert into the following eight major disease categories:– Cardiovascular disease (CARDI).– Renal disease (RENAL).– Peripheral vascular disease (PERIP).– Neurological disease (NEURO).– Metabolic disease (METAB).– Inflammatory (infectious) disease (INFLM).– Ocular (ophthalmologic) disease (OCULR).– Cerebrovascular disease (CEREB).Our objective is to learn models that are able to accurately diagnose each of these major diseases.

  • The PCM output can be any file format which is supported by the PCM to PCM conversion.

  • Metabolic disease contraindicating use of the KD e.g. pyruvate carboxylase deficiency, medium-chain acyl-CoA dehydrogenase (MCAD) deficiency from previous medical investigation and screening at baseline.

  • Main exclusion criteria: Metabolic disease contraindicating use of the KD, e.g. pyruvate carboxylase deficiency, medium-chain acyl-CoA dehydrogenase (MCAD) deficiency.

  • Metabolic disease drug discoveryd"hitting the target" is easier said than done.

  • Crunkhorn, Metabolic disease: New role for HDACs in glucose homeostasis.


More Definitions of Metabolic disease

Metabolic disease means a disease as designated by rule of the state health

Related to Metabolic disease

  • inherited metabolic disease means a disease caused by an inherited abnormality of body chemistry for which testing is mandated by law;

  • Inherited Metabolic Disorder means a disease caused by an inherited abnormality of body chemistry that meets all of the following requirements:

  • Therapeutic diet means meals served that are soft, low-fat, low-sodium or controlled calorie.

  • Acute toxicity means concurrent and delayed adverse effects that result from an acute exposure and occur within any short observation period, which begins when the exposure begins, may extend beyond the exposure period, and usually does not constitute a substantial portion of the life span of the organism.

  • Pivotal Trial means: (a) a human clinical trial that would satisfy the requirements for a Phase 3 study as defined in 21 CFR § 312.21(c) (or any amended or successor regulations); or (b) any other human clinical trial that the applicable Regulatory Authority has agreed, whether before first dosing of the first patient in such trial (e.g., pursuant to a special protocol assessment agreement with the FDA) or after first dosing of the first patient in such trial (e.g., based on an interim data analysis), is sufficient to form the primary basis of an efficacy claim in an NDA submission, regardless of whether the sponsor of such trial characterizes or refers to such trial as a “Phase 3,” “Phase 2b” or “Phase 2b/3” trial (or otherwise) in the applicable protocol, on xxxxxxxxxxxxxx.xxx, or in any other context. If a human clinical trial does ***Certain Confidential Information Omitted

  • Phase III Clinical Trial means a human clinical trial in any country, the results of which could be used to establish safety and efficacy of a Product as a basis for an NDA or would otherwise satisfy requirements of 21 CFR 312.21(c), or its foreign equivalent.

  • Phase IIb Clinical Trial means a relatively longer and larger Phase II Clinical Study designed to study the effectiveness of different doses of a particular Product against placebo or other positive controls for a particular Indication in patients with the disease or condition under study, which is determined by the PDC to be a Phase IIB Clinical Study.

  • Phase III Clinical Trials means those trials on sufficient numbers of patients that are designed to establish that a drug is safe and efficacious for its intended use, and to define warnings, precautions and adverse reactions that are associated with the drug in the to be prescribed dosage range, and supporting Regulatory Approval of such drug.

  • Phase III Clinical Study means, as to a particular Licensed Product, a clinical study in humans that is prospectively designed to assess the safety and effectiveness of such Licensed Product in a manner sufficient to file a Drug Approval Application for the Indication under investigation in the study. Without limiting the generality of the foregoing, a clinical study shall be deemed to be a “Phase III Clinical Study” hereunder if such study has been designated by the sponsor as a Phase III clinical trial on xxx.xxxxxxxxxxxxxx.xxx (or any successor website maintained by the U.S. National Institutes of Health (or any successor agency of the U.S. Government)).

  • Opioid antagonist means a drug that binds to opioid

  • Pivotal Clinical Trial means (i) a human clinical trial of a Product that is intended to be a pivotal trial for obtaining Regulatory Approval (e.g., in the United States such clinical trial is conducted after the end of phase 2 meeting with the FDA) and to otherwise establish safety and efficacy in patients with the disease or condition being studied and to provide an adequate basis for physician labeling, for purposes of filing a MAA for Product, and that would satisfy the requirements under 21 C.F.R. 312.21(c) or foreign equivalents thereof, or (ii) any other clinical trial that is intended to establish that a pharmaceutical product is safe and efficacious for its intended use, and to determine warnings, precautions, and adverse reactions that are associated with such pharmaceutical product in the dosage range to be prescribed, which clinical trial is a registration trial intended to be sufficient for filing an application for a Regulatory Approval for such product in the United States or another country or some or all of an extra-national territory, solely as evidenced by the acceptance for filing for a Regulatory Approval for such product after completion of such clinical trial.

  • Active Compound means a soluble chemical compound that can bind non-covalently to the Collaboration Target or a Target for which such compound is counterscreened, in each case where such compound { * }.

  • Dose is a generic term that means absorbed dose, dose equivalent, effective dose equivalent, committed dose equivalent, committed effective dose equivalent, total organ dose equivalent, or total effective dose equivalent. For purposes of these regulations, "radiation dose" is an equivalent term.

  • Collaboration Compound means any of the following: (a) FG-4592, (b) any HIF Compound (other than FG-4592) that is added to this Agreement pursuant to Section 3.6, and (c) any salts, esters, complexes, chelates, crystalline and amorphous morphic forms, pegylated forms, enantiomers (excluding regioisomers), prodrugs, solvates, metabolites and catabolites of any of the foregoing ((a) or (b)).

  • Massive Multiauthor Collaboration Site (or “MMC Site”) means any World Wide Web server that publishes copyrightable works and also provides prominent facilities for anybody to edit those works. A public wiki that anybody can edit is an example of such a server. A “Massive Multiauthor Collaboration” (or “MMC”) contained in the site means any set of copyrightable works thus published on the MMC site.

  • Biological diversity means the variability among living organisms from all sources including, inter alia, terrestrial, marine and other aquatic ecosystems and the ecological complexes of which they are part; this includes diversity within species, between species and of ecosystems.

  • Lead Compound means any compound of lead other than galena which, when treated in the manner described below, yields to an aqueous solution of hydrochloric acid a quantity soluble lead compound exceeding, when calculated as lead monoxide, five percent of the dry weight of the portion taken analysis.

  • Phase II Clinical Trial means a human clinical trial in any country that is intended to initially evaluate the effectiveness of a Product for a particular indication or indications in patients with the disease or indication under study or would otherwise satisfy requirements of 21 CFR 312.21(b), or its foreign equivalent.

  • Anaerobic digestion means a controlled process involving microbial decomposition of organic matter in the absence of oxygen;

  • Cannabinoid means any of the chemical compounds that are the active constituents of marijuana.

  • Phase II Clinical Trials means those trials on sufficient numbers of patients that are designed to establish safety and assess the biological activity of a drug for its intended use, and to define warnings, precautions and adverse reactions that are associated with the drug in the to be prescribed dosage range.

  • Diagnostic Product means an assemblage of reagents, including but not limited to reagents packaged in the form of a kit, useful in performing a Licensed Service.

  • Public display means the showing of the original or a copy of a work—

  • Vaccine means a specially prepared antigen which, upon administration to a person, will result in immunity and, specifically for the purposes of this rule, shall mean influenza and pneumococcal vaccines.

  • Phase III Study means a human clinical trial that is prospectively designed to demonstrate statistically whether a product is safe and effective for use in humans in a manner sufficient to obtain regulatory approval to market such product in patients having the disease or condition being studied as described in 21 C.F.R. § 312.21(c) (FDCA), as amended from time to time, and the foreign equivalent thereof.

  • Phase II Clinical Study means, as to a particular Licensed Product for a particular indication, a controlled and lawful study in humans of the safety, dose ranging and efficacy of such Licensed Product for such indication, which is prospectively designed to generate sufficient data (if successful) to commence a Phase III Clinical Trial of such Licensed Product for such indication.